The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participant will get is decided by chance. The study will last for about 8 months.
Male or female (sex at birth)
Age 18 years or above at the time of signing the informed consent
History of documented treatment with GLP-1-RA medications with gastrointestinal (GI) adverse effects as the main reason for treatment discontinuation
Not suitable for re-initiation of GLP-1-RA treatment based on medical history and investigator judgement
Female who is pregnant, breast-feeding, or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive methods
Treatment with GLP-1 receptor agonist or GLP-1-RA medication for any indication within 8 weeks before screening
History of type 1 or type 2 diabetes
Glycated haemoglobin (HbA1c) ≥ 6.5 percent (%) (48 millimole per mole [mmol/mol]) as measured by the central laboratory at screening
Parallel
Cagrilintide
DrugCagrilintide will be administered subcutaneously.
Placebo (matched to Cagrilintide)
DrugPlacebo matched to Cagrilintide will be administered subcutaneously.
Percentage of participants on standard dose or higher dose (yes/no) of cagrilintide and placebo
Measured as percentage of participants.
Click on the lead sponsor to view all of their trials.
